BTIG analyst Mark Massaro maintains $Castle Biosciences (CSTL.US)$ with a buy rating, and adjusts the target price from $40 to $45.
According to TipRanks data, the analyst has a success rate of 30.8% and a total average return of -9.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Castle Biosciences (CSTL.US)$'s main analysts recently are as follows:
Castle Biosciences has reported yet another robust quarter, surpassing expectations and achieving GAAP profit for the second sequential quarter. The company's risk/reward profile remains favorable. There appears to be a strong possibility that reimbursement payments for the company's squamous cell carcinoma test could be extended past the fourth quarter. This is supported by the fact that the company has been receiving payments for over two and a half years and has effectively accumulated additional evidence and data that may justify the ongoing coverage under Medicare reimbursement.
Castle Biosciences exhibited a solid third quarter, achieving revenue expectations and demonstrating promising operational expenditure leverage. While overall volumes increased, dermatology volumes fell short of estimates attributable to seasonal patterns, yet the TissueCypher product continued to show impressive momentum.
The determination of coverage for the SCC test will continue to be a focal point, yet it is observed that the company is advancing its volume for other tests, including growth in IDgenetix and TissueCypher. These tests have played a significant role in the robust quarterly results and have been a factor in the enhanced revenue guidance.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
BTIG分析师Mark Massaro维持$Castle Biosciences (CSTL.US)$买入评级，并将目标价从40美元上调至45美元。
根据TipRanks数据显示，该分析师近一年总胜率为30.8%，总平均回报率为-9.3%。
此外，综合报道，$Castle Biosciences (CSTL.US)$近期主要分析师观点如下：
Castle Biosciences已经报告了又一个强劲的季度，超出预期并连续第二个季度实现了符合普通会计准则的盈利。该公司的风险/回报概况仍然有利。公司鳞状细胞癌检测的报销付款很可能会延长至第四季度之后。这得到的支持是，公司已经连续两年半收到付款，并且有效地积累了可能为继续覆盖医疗保险报销提供根据的额外证据和数据。
Castle Biosciences展示了一个稳健的第三季度，实现了营业收入预期，并展示了有希望的运营支出杠杆作用。尽管总成交量有所增加，但由于季节性因素，皮肤科检测成交量未达到预期，然而TissueCypher产品继续展现出强劲的增势。
鳞状细胞癌检测的覆盖范围的确定将继续成为一个焦点，但观察到公司正在推进其他测试的成交量，包括IDgenetix和TissueCypher的增长。这些测试在强劲的季度业绩中发挥了重要作用，并成为增强营业收入指引的因素。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
